We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Diagnostic Biomarkers Uncovered for Rare Kidney Cancer

Diagnostic Biomarkers Uncovered for Rare Kidney Cancer

Diagnostic Biomarkers Uncovered for Rare Kidney Cancer

Diagnostic Biomarkers Uncovered for Rare Kidney Cancer

Credit: iStock
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Diagnostic Biomarkers Uncovered for Rare Kidney Cancer"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Renal cell carcinoma is the most common type of kidney cancer, accounting for about 90% of cases in adults. But there are more than 10 different subtypes, each with important differences at a molecular level that can shape their aggressiveness or their response to treatment.

Using next-generation RNA sequencing techniques, a team of scientists from the University of Michigan Rogel Cancer Center has uncovered the gene signature of chromophobe renal cell carcinoma (ChRCC) and have extensively tested the expression of three new biomarkers. The subtype is the third most common type of renal cell carcinoma, comprising about 5% of cases.

The U-M analysis examined RNA sequencing data from more than 1,000 kidney cancer samples combining profiles from Michigan Medicine patients with others in The Cancer Genome Atlas.

“Our approach identified two genes — Forkhead Box I1 (FOXI1) and Rh family C glycoprotein (RHCG) — and one long non-coding RNA (LINC01187) that are overexpressed in chromophobe renal cell carcinoma and positive in related oncocytic tumors,” says senior study author Rohit Mehra, M.D., an associate professor of pathology at Michigan Medicine and member of the Michigan Center for Translational Pathology.

“We investigated both cancers primary to the kidney as well as those which had spread out, and found strong expression of these three biomarkers,” he adds. “Importantly, we did not find them to be associated with other subtypes of kidney cancer, especially in metastatic state.”

Follow-up work is being conducted to validate the new biomarkers for use in the clinic at U-M and beyond, Mehra notes, where they may be particularly useful in diagnosis of metastatic tumors or a subset of primary tumors that can’t be readily identified under the microscope.

The success of the group’s integrative sequencing analysis approach is helping them develop a more specific kidney cancer diagnostic panel to complement existing tools, Mehra says. He notes the approach allowed the group previously to identify a specific biomarker for another rare kidney cancer called mucinous tubular and spindle cell carcinoma, helping to aid the diagnosis of challenging samples from U-M and other institutions.

The current analysis also points toward the type of cell within a normal kidney from where chromophobe renal cell carcinoma and related cancers originate — a specialized cell in the lining of the small tubules in the kidneys called an intercalated cell. This information could be helpful in future efforts to treat or better classify these tumors.

Importantly, the study also throws light on possible mechanisms that may underlie a variant of the disease called sarcomatoid ChRCC, where the scientists observed a complete lack of FOXI1 and long non-coding RNA. Loss of FOXI1, a key transcription factor, may contribute to de-differentiation in these tumors which tend to be more aggressive and may require additional therapeutic strategies.


Skala et al. (2020) Next-Generation RNA Sequencing-Based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncoyctic Neoplasms. European Urology. DOI: https://doi.org/10.1016/j.eururo.2020.03.003

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.